Churning a stock in an industry that is as heavily regulated, results dependent and slow moving as the health sciences only provides "play" opportunities for the big boys. It only damages ordinary investors chances to gain when a clinical milestone is reached. Any investor who does not understand those simple facts should not invest in biopharma. The old adage of buy on the milestone, sell on the rumor is crazy. Follow clinicaltriasDOTgov, NIH or Medline if you want to know what is happening with biopharma drugs, biological, vaccines and diagnostics. Just close your eyes and look 2-3 months later. But churning only promotes smoke, mirrors and BS on a MB.